Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study ID
NCT06163729
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Gastroesophageal Junction Adenocarcinoma (Siewert II-III)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy — DRUG
    Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks

Study Details

This project intends to study the efficacy and safety of camrelizumab combined with chemotherapy followed by radiotherapy in the perioperative treatment of AEG.

Key Dates

Start date
Aug 25, 2022
Status verified
Dec 2023
Primary completion
May 1, 2025
Completion
May 1, 2028

Study Design

Enrollment
68 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy

Primary Outcome Measure

Pathologic complete response (PCR) [ Time Frame: 4 weeks after surgery ]

Central Contacts